Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stake Lowered by Capital International Inc. CA

Capital International Inc. CA lessened its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 6.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 93,376 shares of the biopharmaceutical company’s stock after selling 6,646 shares during the period. Capital International Inc. CA owned about 0.07% of Alnylam Pharmaceuticals worth $13,955,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Allspring Global Investments Holdings LLC lifted its position in Alnylam Pharmaceuticals by 572.0% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 143 shares in the last quarter. Quent Capital LLC grew its position in shares of Alnylam Pharmaceuticals by 246.0% during the 4th quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 123 shares during the period. Robeco Institutional Asset Management B.V. grew its position in shares of Alnylam Pharmaceuticals by 155.7% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 12,513 shares during the period. GAMMA Investing LLC bought a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth about $52,000. Finally, V Square Quantitative Management LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter worth about $52,000. Institutional investors own 92.97% of the company’s stock.

Insider Buying and Selling

In other news, CEO Yvonne Greenstreet sold 7,093 shares of the stock in a transaction on Thursday, July 11th. The stock was sold at an average price of $261.00, for a total value of $1,851,273.00. Following the sale, the chief executive officer now directly owns 73,441 shares of the company’s stock, valued at $19,168,101. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, CEO Yvonne Greenstreet sold 7,093 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Thursday, July 11th. The stock was sold at an average price of $261.00, for a total transaction of $1,851,273.00. Following the sale, the chief executive officer now owns 73,441 shares of the company’s stock, valued at approximately $19,168,101. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 1,198 shares of the business’s stock in a transaction on Tuesday, June 25th. The shares were sold at an average price of $230.99, for a total value of $276,726.02. Following the transaction, the executive vice president now owns 14,181 shares of the company’s stock, valued at approximately $3,275,669.19. The disclosure for this sale can be found here. Insiders sold 74,450 shares of company stock worth $15,287,984 in the last quarter. 1.50% of the stock is owned by insiders.

Alnylam Pharmaceuticals Price Performance

ALNY stock traded down $3.04 during midday trading on Friday, reaching $234.84. 524,474 shares of the stock were exchanged, compared to its average volume of 882,296. The stock has a market capitalization of $29.70 billion, a PE ratio of -87.63 and a beta of 0.37. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $263.73. The company has a fifty day moving average price of $197.28 and a 200 day moving average price of $172.50.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) EPS for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.23. The business had revenue of $494.33 million for the quarter, compared to the consensus estimate of $428.01 million. During the same quarter last year, the firm posted ($1.40) EPS. The business’s revenue for the quarter was up 54.8% compared to the same quarter last year. As a group, analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -3.99 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently commented on ALNY. Bank of America raised their price objective on shares of Alnylam Pharmaceuticals from $248.00 to $295.00 and gave the stock a “buy” rating in a report on Tuesday, June 25th. Chardan Capital reissued a “buy” rating and set a $225.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, May 3rd. Barclays upped their target price on shares of Alnylam Pharmaceuticals from $236.00 to $291.00 and gave the company an “overweight” rating in a report on Tuesday, June 25th. Stifel Nicolaus lifted their price target on shares of Alnylam Pharmaceuticals from $215.00 to $295.00 and gave the company a “buy” rating in a report on Thursday, June 27th. Finally, UBS Group lifted their price target on shares of Alnylam Pharmaceuticals from $253.00 to $288.00 and gave the stock a “buy” rating in a research note on Friday, June 28th. Eight investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to MarketBeat, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $256.73.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.